<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004075</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067283</org_study_id>
    <secondary_id>U01CA069912</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>990102</secondary_id>
    <nct_id>NCT00004075</nct_id>
  </id_info>
  <brief_title>17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery</brief_title>
  <official_title>A Phase I Trial of 17-Allylaminogeldanamycin (17-AAG) in Solid Tumor and Lymphoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of&#xD;
      17-N-allylamino-17-demethoxygeldanamycin in treating patients with solid tumors that cannot&#xD;
      be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of&#xD;
           17-N-allylamino-17-demethoxygeldanamycin (17-AAG), administered at 2 different dosing&#xD;
           schedules, in patients with unresectable solid tumors.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Assess the effect of this drug on heat shock protein chaperone complex components and&#xD;
           client proteins in lymphoma tissue obtained pre- and post-treatment in patients with&#xD;
           relapsed lymphoma.&#xD;
&#xD;
        -  Determine any response to this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 2 treatment groups.&#xD;
&#xD;
        -  Group I: Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1&#xD;
           hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Group II: Patients receive 17-AAG IV over 1 hour on days 1, 4, 8, and 11. Courses repeat&#xD;
           every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 1-6 solid tumor patients receive escalating doses of 17-AAG until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Once the MTD is determined, 10 patients with either lymphoma or superficial solid tumors&#xD;
      accessible for biopsy are treated as in group II at the MTD.&#xD;
&#xD;
      Patients are followed for 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 58-130 patients (30-72 for group I and 28-58 for group II) will&#xD;
      be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following diagnoses:&#xD;
&#xD;
               -  Histologically or cytologically confirmed solid tumor*&#xD;
&#xD;
                    -  Unresectable disease&#xD;
&#xD;
               -  Hodgkin's or non-Hodgkin's lymphoma&#xD;
&#xD;
                    -  Relapsed disease&#xD;
&#xD;
                    -  Failed at least 1 prior therapy&#xD;
&#xD;
                    -  Neoplastic cells are accessible through biopsy NOTE: *Only patients with&#xD;
                       biopsy-accessible superficial tumors or lymphoma are eligible once the&#xD;
                       maximum tolerated dose has been determined&#xD;
&#xD;
          -  No known standard therapy that is potentially curative or definitely capable of&#xD;
             extending life expectancy exists&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times ULN (5 times ULN if liver involvement)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.25 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective nonhormonal contraception&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
          -  No history of serious allergic reaction to eggs&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent routine or prophylactic use of a colony-stimulating factor (e.g.,&#xD;
             filgrastim [G-CSF] or sargramostim [GM-CSF])&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and&#xD;
             recovered from acute and reversible toxic effects&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent birth control pills&#xD;
&#xD;
          -  No concurrent steroids as anti-emetics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of the bone marrow&#xD;
&#xD;
          -  No prior radiopharmaceuticals&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent 3A4 enzyme inhibitors (e.g., verapamil, erythromycin, miconazole, or&#xD;
             ketoconazole)&#xD;
&#xD;
          -  No concurrent investigational ancillary therapy&#xD;
&#xD;
          -  No concurrent enrollment in another study involving a pharmacologic agent (e.g.,&#xD;
             drugs, biologics, immunotherapy approaches, or gene therapy) for symptom control or&#xD;
             therapeutic intent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Erlichman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 2, 2011</last_update_submitted>
  <last_update_submitted_qc>August 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Charles Erlichman, M.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

